Group 1 - The biotechnology company Baoyi Pharmaceutical-B (02659) has completed its subscription period from December 2 to 5, with trading expected to commence on December 10 [1] - Market statistics indicate that Baoyi Pharmaceutical has borrowed HKD 269.21 billion from brokers for margin trading, significantly exceeding the public offering amount of HKD 100 million, resulting in an oversubscription of 2,690.8 times [1] - The company plans to issue 37.912 million H-shares, with 10% allocated for public offering at a price of HKD 26.38 per share, aiming to raise HKD 100 million [1] Group 2 - The entry fee for one lot of shares (100 shares) is HKD 2,664.6 [1] - CICC and Haitong International are the joint sponsors for the offering [1] - Baoyi Pharmaceutical has secured cornerstone investors including Anke Biotechnology Hong Kong, DC Alpha SPC, and Guotai Junan Securities, with an investment amount of HKD 200 million [1]
新股消息 | 宝济药业-B(02659)招股结束 孖展认购额录得2692.1亿港元 超购2690.8倍